Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 MutationHenriette Huber,Eugen Tausch,Christof Schneider,Simone Edenhofer,Julia Von Tresckow,Sandra Robrecht,Adam Giza,Can Zhang,Moritz Furstenau,Peter Dreger,Matthias Ritgen,Thomas Illmer,Anna Lena Illert,Jan Dürig,Sebastian Böttcher,Carsten Utoft Niemann,Michael Kneba,Anna-Maria Fink,Kirsten Fischer,Hartmut DöhnerBlood（2022）引用 1|浏览18暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
